Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Patients with Multiple Myeloma (MM) and patients with documented bone metastases from solid tumors, in conjunction with standard anti-neoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy and Hypercalcemia of Malignancy (HCM).